It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants, contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta

Combination of Humalog with pioglitazone: Cases of cardiac failure have been reported when pioglitazone was used in loss of consciousness, coma, or death.

Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include Hypoglycemia.

Not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the be rotated so that the same site is not used more than approximately once a month.

Therapeutic indications

Humalog® is indicated for the treatment of diabetes mellitus in patients requiring insulin for the maintenance of normal glucose homeostasis. Humalog®® is also indicated for the stabilization of diabetic ketosis in patients with type 1 diabetes mellitus. It may be used in combination with oral agents, other insulin.

Pharmacotherapeutic group: Fast-acting human insulin analogue. ATC code: A10A B04

Humalog® is available in pack of 5 x 3 mL Pens and/or the glass cartridges. The 3 mL cartridges are sealed in a disposable pen injector called the "KwikPen®" and are secured with aluminium seals. Dimeticone or silicone emulsion may be used to treat the cartridge plungers, and the cartridges are cleaned with a clean cloth or paper towel before being rinsed with a 0.9% saline solution.

Each mL of Insulin lispro contains: 100 IU (equivalent to 3.5 mg) Insulin lispro I.P. (r-DNA origin) as active ingredient, Hydrochloric Acid, Sodium Chloride, Water for Injection.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

In patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycaemia when used in combination with other insulin.

The pharmacokinetics of insulin lispro in children is in those with diabetes mellitus.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

As with all insulin preparations, the time course of insulin lispro action may vary in different individuals or at different physiological conditions, be it intra- or inter-individual variations. The time course of action may be affected by several factors.

The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels (20 to 30 minutes) as quickly as 15 minutes. Insulin lispro is effective immediately after injection and action is not significantly prolonged by an increase in insulin lispro dose.

Hypoglycaemia may be associated with tachycardia, confusion, hypotension, feeling ill, sweating, and/or the ingestion of small quantities of alcohol.

The above representation reflects the relative amount of glucose over time required to maintain the subjects’ whole glucose concentrations near target levels and is an indication of the effect of these insulin on glucose metabolism under basal and postprandial conditions.

In patients with type 2 diabetes have demonstrated reduced postprandial hyperglycaemia when used in combination with other insulin.

Each mL of Insulin lispro contains: 100 IU (equivalent to 3.5 mg) Insulin lispro I.P. (r-DNA origin) as active ingredient, Hydrochloric Acid, Sodium Chloride, Water for Injection.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

Each mL of Insulin lispro contains: 100 IU (equivalent to 3.5 mg) Insulin lispro I.P. (r-DNA origin) as active ingredient, Hydrochloric Acid, Sodium Chloride, Water for Injection.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic effects are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion and dialing the Pen is more difficult, change the needle and prime the Pen.
DIE ID

COLORS:
BLACK F

PACKAGING SITE:

__ INDY DRY    X PDAP    __ OTHER

OTHER REGULATED ITEMS: N/A

ALRP INFORMATION

LILLY INDIANAPOLIS PPD SITE

GRAPHICS

ITEM CODE & VERSION NO: PA001DAIN02_P1V1
SUPERSEDES: PA001DAIN01

CREATED BY: EF    DATE: 22 Jul 2015

FLAT DIMENSIONS: 13.25" x 20"
FOLDED DIMENSIONS: 4.5" x 2.25"

TEMPLATE NO: L-0239A